Bicara Therapeutics is progressing its Phase 3 trial of ficerafusp alfa for head and neck cancer, expecting interim results by mid-2027 that could support accelerated approval. The company holds nearly $500 million in cash and securities, funding operations into early 2029. Despite a Q2 net loss of $55.4 million, analysts remain optimistic, raising price targets to $35 and $39. This financial strength and clinical progress position Bicara as a promising player in cancer therapy development.
Mercury Systems reported a Q4 EPS of $0.37, slightly below analyst estimates of $0.38, but exceeded revenue expectations with $289.78 million, a 6.1% increase year-over-year. The company showed robust demand with record bookings of $660 million and a...
Klarna shares dropped 22.81% after cutting its earnings outlook and announcing leadership changes, raising investor concerns. Fabrinet's stock fell 19.38% despite strong quarterly results due to a broader sell-off in AI infrastructure stocks. Leverag...
ProPhase Labs' stock soared 506.62% to $27.48 following a 1-for-4 reverse stock split aimed at consolidating shares and boosting price per share. Other notable gainers include Inpixon (+113%), Super League Gaming (+82%) after a major Bitcoin investme...
American Airlines is bringing back seatback entertainment screens and adding premium seats to its narrowbody jets starting in 2028. This move responds to traveler demand, especially from younger passengers, and aims to close the profit gap with compe...
Grocery Outlet Holding Corp. reported a 1.1% revenue increase to $1.19 billion in Q2 2026 and an adjusted EPS of $0.20, beating analyst expectations despite a 13% EPS decline. The company is undergoing strategic restructuring, including closing 36 un...
